Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk

References

• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–1685.
   PubMed Web of Science ®Google Scholar
• Thakkar B, Aronis KN, Vamvini MT, et al. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013;62:922–934.
   PubMed Web of Science ®Google Scholar
• Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2:57.
   PubMedGoogle Scholar
• Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4059–4067.
   PubMed Web of Science ®Google Scholar
• Payen L, Delugin L, Courtois A, et al. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Brit J Pharmacol. 2001;132:778–784.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Inoue T, Murai M, et al. Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: role for ATP-sensitive K+ channels and endoplasmic reticulum stress. Int J Oncol. 2012;41:465–475.
   PubMed Web of Science ®Google Scholar
• Qian X, Li J, Ding JH, et al. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH(2)-terminal kinase pathway in human gastric cancer cell tine MGC-803. Biochem Pharmacol. 2008;76:1705–1715.
   PubMed Web of Science ®Google Scholar
• Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010;53:1838–1845.
   PubMed Web of Science ®Google Scholar
• Zhang PH, Chen ZW, Lv D, et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health. 2012;12:567.
   PubMed Web of Science ®Google Scholar
• Noto H, Osame K, Sasazuki T, et al. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications. 2010;24:345–353.
   PubMed Web of Science ®Google Scholar
• Lee MY, Lin KD, Hsiao PJ, et al. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism. 2012;61:242–249.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033.
   PubMed Web of Science ®Google Scholar
• Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014;38:330–336.
   PubMedGoogle Scholar
• Duan W, Shen X, Lei J, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int. 2014;2014:461917.
   PubMed Web of Science ®Google Scholar
• Novosyadlyy R, Lann DE, Vijayakumar A, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 2010;70:741–751.
   PubMed Web of Science ®Google Scholar
• Ferguson RD, Novosyadlyy R, Fierz Y, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res. 2012;14:R8.
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904–910.
   PubMed Web of Science ®Google Scholar
• Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, et al. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta. 2011;1807:664–678.
   PubMed Web of Science ®Google Scholar
• Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. Jama. 2005;293:194–202.
   PubMed Web of Science ®Google Scholar
• Stocks T, Rapp K, Bjorge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. Plos Medicine. 2009;6:e1000201.
   PubMed Web of Science ®Google Scholar
• Joshu CE, Prizment AE, Dluzniewski PJ, et al. Glycated hemoglobin and cancer incidence and mortality in the atherosclerosis in communities (ARIC) study, 1990-2006. Int J Cancer. 2012;131:1667–1677.
   PubMed Web of Science ®Google Scholar
• Travier N, Jeffreys M, Brewer N, et al. Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study. Ann Oncol. 2007;18:1414–1419.
   PubMed Web of Science ®Google Scholar
• Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Investig. 2012;3:24–33.
   PubMed Web of Science ®Google Scholar
• Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101.
   PubMed Web of Science ®Google Scholar
• Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci. 2016;61:636–645.
   PubMed Web of Science ®Google Scholar
• Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928–1937.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–1648.
   PubMed Web of Science ®Google Scholar
• Luo W, Cao Y, Liao C, et al. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Dis. 2012;14:1307–1312.
   PubMed Web of Science ®Google Scholar
• Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57:1576–1585.
   PubMed Web of Science ®Google Scholar
• Tseng CH. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 2012;167:409–416.
   PubMed Web of Science ®Google Scholar
• Jeon JY, Jeong DH, Park MG, et al. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. Plos One. 2013;8:e55196.
   PubMed Web of Science ®Google Scholar
• Ge Z, Ben Q, Qian J, et al. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2011;23:1127–1135.
   PubMed Web of Science ®Google Scholar
• Tian T, Zhang LQ, Ma XH, et al. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes. 2012;120:217–223.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang X, Gu C, et al. Influence of diabetes mellitus on mortality in breast cancer patients. ANZ J Surg. 2015;85:972–978.
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Fischer HD, Austin PC, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Res Treat. 2015;150:613–620.
   PubMed Web of Science ®Google Scholar
• Tseng CH. Type 2 diabetes mellitus and kidney cancer risk: a retrospective cohort analysis of the national health insurance. Plos One. 2015;10:e0142480.
   PubMed Web of Science ®Google Scholar
• Bansal D, Bhansali A, Kapil G, et al. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151–158. S1
   PubMed Web of Science ®Google Scholar
• Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115:2047–2058. .
   PubMed Web of Science ®Google Scholar
• Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006;86:849–899.
   PubMed Web of Science ®Google Scholar
• Kim JA, Kang YS, Lee SH, et al. Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels and intracellular Ca(2+) release in HepG2 human hepatoblastoma cells. Biochem Biophys Res Commun. 1999;261:682–688.
   PubMed Web of Science ®Google Scholar
• Golstein PE, Boom A, Van Geffel J, et al. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999;437:652–660.
   PubMed Web of Science ®Google Scholar
• Lautier D, Canitrot Y, Deeley RG, et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol. 1996;52:967–977.
   PubMed Web of Science ®Google Scholar
• Hsia TC, Lin CC, Wang JJ, et al. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung. 2002;180:173–179.
   PubMed Web of Science ®Google Scholar
• Rudas M, Filipits M, Taucher S, et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat. 2003;81:149–157.
   PubMed Web of Science ®Google Scholar
• Zalcberg J, Hu XF, Slater A, et al. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis. 2000;3:66–75.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, et al. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52:249–273.
   PubMed Web of Science ®Google Scholar
• Pardo LA. Voltage-gated potassium channels in cell proliferation. Physiology. 2004;19:285–292.
   PubMed Web of Science ®Google Scholar
• Felipe A, Vicente R, Villalonga N, et al. Potassium channels: new targets in cancer therapy. Cancer Detect Prev. 2006;30:375–385.
   PubMedGoogle Scholar
• Comes N, Bielanska J, Vallejo-Gracia A, et al. The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer. Front Physiol. 2013;4:283.
   PubMed Web of Science ®Google Scholar
• Stringer BK, Cooper AG, Shepard SB. Overexpression of the G-protein inwardly rectifying potassium channel 1 (GIRK1) in primary breast carcinomas correlates with axillary lymph node metastasis. Cancer Res. 2001;61:582–588.
   PubMed Web of Science ®Google Scholar
• Busija DW, Lacza Z, Rajapakse N, et al. Targeting mitochondrial ATP-sensitive potassium channels–a novel approach to neuroprotection. Brain Res Brain Res. 2004;46:282–294.
   PubMedGoogle Scholar
• Ardehali H, O’Rourke B. Mitochondrial K(ATP) channels in cell survival and death. J Mol Cell Cardiol. 2005;39:7–16.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Gonoi T, Clement JP, et al. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron. 1996;16:1011–1017.
   PubMed Web of Science ®Google Scholar
• Yasukagawa T, Niwa Y, Simizu S, et al. Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells. FEBS Lett. 2012;586:1504–1509.
   PubMed Web of Science ®Google Scholar
• Wondergem R, Cregan M, Strickler L, et al. Membrane potassium channels and human bladder tumor cells: II growth properties. J Membr Bio. 1998;161:257–262.
   PubMed Web of Science ®Google Scholar
• Abdul M, Hoosein N. Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett. 2002;186:99–105.
   PubMed Web of Science ®Google Scholar
• Abdul M, Hoosein N. Voltage-gated potassium ion channels in colon cancer. Oncol Rep. 2002;9:961–964.
   PubMed Web of Science ®Google Scholar
• Malhi H, Irani AN, Rajvanshi P, et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J. Biol Chem. 2000;275:26050–26057.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Kwan HY, Chan HC, et al. Blockage of voltage-gated K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells. Int J Mol Med. 2003;11:261–266.
   PubMed Web of Science ®Google Scholar
• Nunez M, Medina V, Cricco G, et al. Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. Bmc Pharmacol Toxico. 2013;14:6.
   Web of Science ®Google Scholar
• Woodfork KA, Wonderlin WF, Peterson VA, et al. Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol. 1995;162:163–171.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5:475–477.
   PubMed Web of Science ®Google Scholar
• Sugawara K, Shibasaki T, Takahashi H, et al. Structure and functional roles of Epac2 (Rapgef4). Gene. 2016;575:577–583.
   PubMed Web of Science ®Google Scholar
• Cocca C, Martin G, Nunez M, et al. Effect of glibenclamide on N-nitroso-N-methylurea-induced mammary tumors in diabetic and nondiabetic rats. Oncol Res. 2005;15:301–311.
   PubMed Web of Science ®Google Scholar
• Rong Z, Li L, Fei F, et al. Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer. J Exp Clin Canc Res. 2013;32:32.
   PubMed Web of Science ®Google Scholar
• Bo S, Castiglione A, Ghigo E, et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol. 2013;169:117–126.
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–258.
   PubMed Web of Science ®Google Scholar
• Kowall B, Rathmann W, Kostev K. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Diabetes Care. 2015;38:59–65.
   PubMed Web of Science ®Google Scholar
• Mamtani R, Pfanzelter N, Haynes K, et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care. 2014;37:1910–1917.
   PubMed Web of Science ®Google Scholar
• Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007;23:479–484.
   PubMed Web of Science ®Google Scholar
• Qiu H, Rhoads GG, Berlin JA, et al. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:349–357.
   PubMed Web of Science ®Google Scholar
• Ruiter R, Visser LE, Van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012;35:119–124.
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2015;31:619–626. .
   PubMed Web of Science ®Google Scholar
• Tuccori M, Wu JW, Yin H, et al. The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes. Diabetes Care. 2015;38:2083–2089.
   PubMed Web of Science ®Google Scholar
• Yang X, So WY, Ma RC, et al. Use of sulphonylurea and cancer in type 2 diabetes-the Hong Kong diabetes registry. Diabetes Res Clin Pract. 2010;90:343–351.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Becker C, Meier C, et al. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:280–286.
   PubMed Web of Science ®Google Scholar
• Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30:750–758.
   PubMed Web of Science ®Google Scholar
• Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes & Control: CCC. 2009;20:1617–1622.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 2012;107:620–626.
   PubMed Web of Science ®Google Scholar
• Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2011;34:129–131.
   PubMed Web of Science ®Google Scholar
• Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116:1938–1946.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Taniguchi E, Morita Y, et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int. 2010;30:479–486.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Becker C, Meier C, et al. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011;123:200–204.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33:1304–1308.
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Tammela TL, Lahtela J, et al. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol. 2008;168:925–931.
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009;46:279–284.
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Allen NE, Appleby PN, et al. Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;136:372–381.
   PubMed Web of Science ®Google Scholar
• Jian Gang P, Mo L, Lu Y, et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40:54–61.
   PubMed Web of Science ®Google Scholar
• Gu Q, Wang C, Wang G, et al. Glipizide suppresses embryonic vasculogenesis and angiogenesis through targeting natriuretic peptide receptor A. Exp Cell Res. 2015;333:261–272.
   PubMed Web of Science ®Google Scholar
• Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–1908.
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012;55:2593–2603.
   PubMed Web of Science ®Google Scholar
• Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. The Oncologist. 2012;17:813–822.
   PubMed Web of Science ®Google Scholar
• Jennings PE, Scott NA, Saniabadi AR, et al. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism. 1992;41:36–39.
   PubMed Web of Science ®Google Scholar
• Sliwinska A, Rogalska A, Szwed M, et al. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep. 2012;39:5253–5267.
   PubMed Web of Science ®Google Scholar
• Sliwinska A, Sliwinski T, Kasznicki J, et al. Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol. 2010;61:347–353.
   PubMed Web of Science ®Google Scholar
• Qi C, Zhou Q, Li B, et al. Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget. 2014;5:9966–9979.
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385–411.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33:1224–1229.
   PubMed Web of Science ®Google Scholar
• Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389–394.
   PubMed Web of Science ®Google Scholar
• Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet. 2005;6:123–142.
   PubMed Web of Science ®Google Scholar
• Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35:2665–2673. .
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492–499.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’aniello S, Vahey S, et al. Time-window bias in case-control studies: statins and lung cancer. Epidemiology. 2011;22:228–231.
   PubMedGoogle Scholar